Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences (EW) to $87 from $89 and keeps a Hold rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Positive Outlook for Edwards Lifesciences Amid CMS Coverage Expansion for TAVR Procedures
- Buy Rating for Edwards Lifesciences Amid Potential TAVR Coverage Expansion and Strategic Alignment
- Edwards Lifesciences: Buy Rating Backed by Strategic Initiatives and Expanding Market Potential
- Edwards Lifesciences price target lowered to $87 from $88 at Baird
- Edwards Lifesciences Completes Key Study on SAPIEN XT THV